Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells.
about
Transglutaminase is a tumor cell and cancer stem cell survival factorTransglutaminase 2 has opposing roles in the regulation of cellular functions as well as cell growth and deathCellular functions of tissue transglutaminaseTissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cellsEvidence that aberrant expression of tissue transglutaminase promotes stem cell characteristics in mammary epithelial cellsSmall molecule inhibitors target the tissue transglutaminase and fibronectin interactionCompensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor TreatmentClinical and biological significance of tissue transglutaminase in ovarian carcinoma.Transglutaminase regulation of cell function.Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival.GPR56 in cancer progression: current status and future perspective.Elongation factor-2 kinase regulates TG2/β1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasionCharacterization of distinct sub-cellular location of transglutaminase type II: changes in intracellular distribution in physiological and pathological statesThe role of TG2 in regulating S100A4-mediated mammary tumour cell migrationActivation of the mTOR signaling pathway in breast cancer MCF‑7 cells by a peptide derived from Porphyra yezoensis.Role of tissue transglutaminase 2 in the acquisition of a mesenchymal-like phenotype in highly invasive A431 tumor cells.Two isoforms of tissue transglutaminase mediate opposing cellular fates.Transglutaminase 2 expression and its prognostic significance in clear cell renal cell carcinoma.Transglutaminase 2: a molecular Swiss army knife.Methylthioadenosine (MTA) Regulates Liver Cells Proteome and Methylproteome: Implications in Liver Biology and DiseaseAtaxia-Telangiectasia, Mutated (ATM)/Nuclear Factor κ light chain enhancer of activated B cells (NFκB) signaling controls basal and DNA damage-induced transglutaminase 2 expression.The opposite effects of doxorubicin on bone marrow stem cells versus breast cancer stem cells depend on glucosylceramide synthaseEvidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells.Tissue transglutaminase: a new target to reverse cancer drug resistanceIodine and doxorubicin, a good combination for mammary cancer treatment: antineoplastic adjuvancy, chemoresistance inhibition, and cardioprotection.Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling.Doxorubicin induces the persistent activation of intracellular transglutaminase 2 that protects from cell deathTissue transglutaminase-1 promotes stemness and chemoresistance in gastric cancer cells by regulating Wnt/β-catenin signaling.Methylglyoxal in cells elicits a negative feedback loop entailing transglutaminase 2 and glyoxalase 1.Imaging aspects of the tumor stroma with therapeutic implications.Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia.Potential of transglutaminase 2 as a therapeutic target.TG2, a novel extracellular protein with multiple functions.Transglutaminases: key regulators of cancer metastasis.Transglutaminase 2 and NF-κB: an odd couple that shapes breast cancer phenotype.The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer.Transglutaminase 2 in cancer.miR-19-Mediated Inhibition of Transglutaminase-2 Leads to Enhanced Invasion and Metastasis in Colorectal Cancer.Transglutaminase 2 reprogramming of glucose metabolism in mammary epithelial cells via activation of inflammatory signaling pathways.Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
P2860
Q26799862-EFCDE42E-3B0D-4FD6-9747-138BD7944BD0Q28069852-5F8189CC-B097-4577-A97E-AFD20CFC743AQ28260600-FC7ECC5C-F0FF-4811-A609-96AA9C6A2DC1Q28475746-BAA2080D-7056-408A-A05A-77F94C1A938CQ28478491-0EE8CC53-61E0-432D-8AEA-9A784C28FAD8Q28540004-9B7C41D2-AE5C-4DBE-B6CF-27EC1A1F1500Q28550149-0E5252FC-40D2-473F-B8F0-9CA1CF03B517Q30483685-B1C89BC3-776B-4320-ABC9-20AAF93D5AE7Q33707936-65C7860C-A334-4BA2-98B0-F767AB1D7EADQ33728989-71DC9410-9C68-4008-81FE-CB0FBB763FD3Q34269343-9122BB12-0A61-4FEE-8912-25F65CFA3AC0Q34473662-39995B76-CD30-44D1-B547-1904C7C43F8EQ34517980-DA911505-C58B-41E4-BA53-F2DB8C2FD0E1Q34613001-E31BE57D-77BC-4B12-9BE2-C6F37A3AA4D8Q34626081-AED9E10C-1FF1-44D6-BD99-67BF13C8134FQ35147626-E4E77B06-5ABA-46EE-A5CB-B7E4AD12192EQ35157424-54B0E645-D65A-4B6A-BB84-9E3C1513E32FQ35170748-DAB52719-F73F-490F-9FE3-115EABA3C624Q35693361-8919E3A3-13BB-4C0E-B599-F5261000F276Q35906658-A5B88FF7-0DDA-4D18-991A-EE7158C2DFDAQ36003028-B0978BF9-87D2-4037-97A5-6276EBD07263Q36269159-1693BB21-8E23-40E8-A01A-C0AB1BAC4674Q36393086-4ED5F501-2DE4-40B8-95EF-73B5BD74802FQ36503511-5D04F16B-8765-4298-AF89-B078D5311611Q36905722-824C166C-540A-46CD-A053-AEB0F600515CQ36916874-E9F148A4-BF16-410E-A241-F8FE4B51C6C4Q37461477-5ADEBC73-822B-4F0C-ADB5-E33939EA0004Q37514770-8C89D298-7694-4BF3-8D5E-9DBE0508FF7BQ37541015-4BB96748-0C38-493C-B4EF-D5F2247442BBQ37626064-2C695684-4564-4D8D-BEEC-AD40BABA7DADQ37745215-34BDFB1D-FA26-4FE7-B505-516ECD2BC399Q37776508-5E0EB752-3A4D-464E-B053-81730DFAC85DQ37912042-F03A0425-FAD9-4F89-82FD-89C1E0AA50C1Q37981102-75ACDB1F-0B40-497A-ABA4-41D5E4510946Q38065965-58B96D01-4964-4C94-BC7F-1874C7E097BDQ38294813-D2861FE4-7CE0-4B15-AB31-21B56430579FQ38648421-8BF2A159-67DF-433F-99DC-997E9B0DE4AAQ38879949-5BD98517-45DB-4B70-B907-FA3E5486E4D2Q39029196-51E3F45D-01DA-4EAF-9718-7B59B5539466Q39268578-D23E3B22-A564-4599-9127-61D853A7D0C3
P2860
Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Implications of increased tiss ...... t breast cancer (MCF-7) cells.
@en
type
label
Implications of increased tiss ...... t breast cancer (MCF-7) cells.
@en
prefLabel
Implications of increased tiss ...... t breast cancer (MCF-7) cells.
@en
P2093
P356
P1433
P1476
Implications of increased tiss ...... t breast cancer (MCF-7) cells.
@en
P2093
P2888
P304
P356
10.1038/SJ.ONC.1209324
P407
P577
2006-05-01T00:00:00Z
P5875
P6179
1008170595